SCHEMBL11920128

SCHEMBL11920128

N#Cc1cccc(OCCCOCCCN2C(=O)c3ccccc3C2=O)c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.63
MAPT P10636 5/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
KMT2A Q03164 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 3/20 0.49
ALDH1A1 P00352 4/20 0.48
HPGD P15428 3/20 0.48
NPSR1 Q6W5P4 1/20 0.47
NPC1 O15118 1/20 0.46
TBXAS1 P24557 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HRH1 P35367 1/20 0.44
CCR3 P51677 1/20 0.44
GRM5 P41594 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740077 0.82 RAB9A (0.72) RAB9AMAPTSMN1; SMN2KMT2ATDP1
SCHEMBL7299163 0.79 RAB9A (1.00) RAB9AMAPTSMN1; SMN2KMT2ATDP1
SCHEMBL8484092 0.78 RAB9A (0.66) RAB9AMAPTSMN1; SMN2KMT2ATDP1
SCHEMBL7124864 0.78 RAB9A (0.64) RAB9AMAPTSMN1; SMN2KMT2ATDP1
SCHEMBL11920129 0.77 RAB9A (0.54) RAB9AMAPTSMN1; SMN2KMT2ATDP1
SCHEMBL6542913 0.77 RAB9A (0.56) RAB9AMAPTSMN1; SMN2KMT2ATDP1
SCHEMBL950598 0.76 HPGD (0.59) RAB9AMAPTSMN1; SMN2KMT2ATDP1
SCHEMBL7057916 0.76 HRH1 (0.59) HRH1CCR3
SCHEMBL10557663 0.76 MAPT (0.69) RAB9AMAPTSMN1; SMN2KMT2ATDP1
SCHEMBL10677584 0.76 RAB9A (0.75) RAB9AMAPTSMN1; SMN2KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
WO-2010139966-A1 AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS OSLO UNIVERSITY HOSPITAL HF (NO) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 RAB9A 3968/4885MAPT 2763/4885SMN1; SMN2 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.